SHANGHAI PHARMACEUTICALS HOLDING CO., LTD |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 17.6 CNY | -1.12% |
|
+0.46% | +5.20% |
Strengths
- The company shows low valuation levels, with an enterprise value at 0.29 times its sales.
- The company appears to be poorly valued given its net asset value.
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
- Analyst opinion has improved significantly over the past four months.
Weaknesses
- As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
- Low profitability weakens the company.
- The company is highly valued given the cash flows generated by its activity.
- Revenue estimates are regularly revised downwards for the current and coming years.
- For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
- For the last twelve months, the analysts covering the company have given a bearish overview of EPS estimates, resulting in frequent downward revisions.
- The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.
- The group usually releases earnings worse than estimated.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Pharmaceuticals
| 1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
|---|---|---|---|---|
| +5.20% | 8.07B | B | ||
| +14.88% | 69.91B | C+ | ||
| +5.87% | 8.32B | C | ||
| -20.43% | 7.97B | B- | ||
| +0.73% | 4.56B | B- | ||
| +16.98% | 4.31B | B+ | ||
| -2.00% | 3.99B | B- | ||
| -2.89% | 3.87B | B | ||
| +21.87% | 3.63B | C+ | ||
| +6.45% | 3.3B | C |
Investor Rating
Trading Rating
ESG Refinitiv
Financials
Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances
Valuation
P/E ratio
EV / Sales
Price to Book
Price to Free Cash Flow
Yield
Momentum
1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision
Consensus
Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion
Business Predictability
Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality
Environment
Emissions
Innovation
Use of resources
Governance
CSR Strategy
Management
Shareholders
Controversy
Controversy
Technical analysis
ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
- Stock Market
- Equities
- 601607 Stock
- Ratings Shanghai Pharmaceuticals Holding Co., Ltd
